SurModics Pharmaceuticals, a SurModics company, is a product-focused, drug-delivery company based in Birmingham, Alabama. SurModics Pharmaceuticals' drug-delivery technologies include long-acting parenteral formulations -- injectable microparticles and injectable solid implants - for the delivery of peptides, small molecules, proteins, antibodies, nucleic acids, and other biological macromolecules. SurModics Pharmaceuticals' capabilities include development of physician-administered and self-administered formulations that are effective for days and months following a single administration. Client-partnered development programs begin with evaluation studies, and then proceed to preclinical development, clinical trial manufacturing and commercial manufacturing. Contract manufacturing of clinical supplies and commercial product includes production of drug-delivery formulations such as microparticles, nanoparticles, liposomes, implants, and microparticles of hydrophobic salts. SurModics Pharmaceuticals' manufactures Lakeshore BiomaterialsTM biodegradable polymers for drug delivery products and medical devices.
Genzyme Pharmaceuticals, a business unit of Genzyme Corporation, provides an integrated resource of custom manufacturing, value-added technologies, and strategic relationships focused in the peptide, lipid, amino acid derivative and drug delivery markets to link and support various stages of drug development for customers in the pharmaceutical and biotechnology industries.
Over 25 years experience in custom manufacturing projects enables Genzyme Pharmaceuticals to focus on process development, GMP manufacturing, and regulatory support of custom pharmaceutical specialties, APIs, and custom synthesis of high performance products. Genzyme Pharmaceuticals’ facility, located in Liestal, Switzerland, contains state-of-the-art equipment and holds a current GMP Certificate. It has been inspected by the Swiss Regulatory Agency, the US FDA, numerous customers, and Genzyme Corporate Quality Compliance. A stringent quality control system in process development, scalable production, and analysis makes Genzyme Pharmaceuticals a reliable partner for the supply of high-quality products and services.
Genzyme Pharmaceuticals also offers two novel drug delivery technologies. LipoBridge® is a proprietary technology specifically designed to facilitate transport of active drug compounds across the blood brain barrier (BBB) and into the Central Nervous System (CNS) via the tight junctions. LipoMaskTM is designed to increase the circulation half life of active drug substances in blood serum and can be developed for both passive and active targeting.
www.genzymepharmaceuticals.com